FDA advisers back Pfizer’s COVID-19 vaccine for young kids

Coronavirus

This October 2021 photo provided by Pfizer shows kid-size doses of its COVID-19 vaccine in Puurs, Belgium. The vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday, Oct. 22, as the U.S. considers opening vaccinations to that age group. (Pfizer via AP)

WASHINGTON (AP) – U.S. health advisers have endorsed kid-size doses of Pfizer’s COVID-19 vaccine for younger children. The vote Tuesday by the Food and Drug Administration panel moves the U.S. closer to vaccinating children ages 5 to 11.

The FDA isn’t bound by the panel’s recommendation and is expected to make its own decision within days. If regulators agree, shots could begin as early as late next week.

Young kids would get a third of the dose given to teens and adults. A study found kid-size vaccinations are nearly 91% effective at preventing infections that cause symptoms. Moderna also is studying its vaccine for young children.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Continuing The Conversation
See Full Weather Forecast

Trending Stories

Don't Miss!

More Don't Miss

Your Guide To
Coronavirus

KELOLAND News is covering the Coronavirus outbreak. We have created a guide to everything you need to know to prepare. We also have the latest stories from across the globe feeding into this page.